COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc ...

#researchneverstops | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Evotec SE (NASDAQ:EVO) Business Update Conference Call January 22, 2024 9:00 AM ET Company Participants Volker Braun - SVP, Head of Global IR & ESG Iris Löw-Friedrich - Chairwoman Mario Polywka - Interim CEO Conference Call Participants Charles Weston - RBC Capital Markets Falko Friedrichs - Deutsche Bank Michael Ryskin - Bank of America Merrill Lynch Steven Mah - TD Cowen Christian Ehmann - Warburg Research Operator At this time, it is my pleasure to hand over to Mr. Volker Braun, Head of Global Investor R ...

If you go forward in this presentation and if we jump back to our governance, and to our impact that we want to have as a company, let me highlight that it was important -- that it is very important and you see it on page number 21, that near-term Science Based Targets are validated and approved now. Why is this important because we always said we want to keep our ESG promises and have aligned our commitment here with our partners to follow the Paris goals. And if you go to page 22, we want to thank the ana ...

| --- | --- | --- | |---------------------------------------------------|-------|-------| | | | | | Evotec SE, 9M 2023 results call, 08 November 2023 | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Werner Lanthaler - CEO Laetitia Rouxel - CFO Cord Dohrmann - CSO Matthias Evers - Chief Business Officer Conference Call Participants Peter Verdult - Citigroup James Quigley - Morgan Stanley Wolf Chanoff - Bank of America Steven Mah - TD Cowen Joseph Hedden - Rx Securities Charles Weston - RBC Capital Markets Douglas Tsao - H.C. Wainwright Operator Werner Lanthaler I would now like to turn the conference over to Werner Lanthaler, CEO. Please go ahead. Thank you very much. Welcome to all of you. Welcome to o ...

| --- | --- | |---------------------------------|-------| | | | | | | | Emerging stronger | | | Pipeline building gaining speed | | Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Exhibit 99.1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) ...

Exhibit 99.1 NHHB5EoCoDaESPR(pAsAibOpnNSLi(oIU(sdrNtrn nn hm etieh hg2ffd o reoef ihov ntocc uooa oe e a n ats c rf c re n ar ha ai ehMM9 d s rtguo qq e eg ts retlm rt a t tli mc.ias t cd uti ni a r ur e sr rf ct9 r alt tuut i) sf ee ees u Nie taa e o e ht se aye k ii db ei ai rc tri hy0 lcn ii 4obl dn tp m a l, cjj sssdn h esc ls eaiCu y, moo ) ea I r o0g n .nl 5 t l ii i l d cs o o dee w t S7 e fr tt Si ewrr nCt oS s lF os g 3Ni o eii .pg o) d i e w l ao)oof d no u tdtHH tf 0u 9 i %E o in r D e d a iYaNr ...